Check our 5 top-rated vape shops of 2024 for a wide variety of vape pen product options for smooth vaping sessions.

Drug giant Novo Nordisk just reported some clinical trial ... In the treatment group, 40.4% of patients lost at least 25% of their total mass. These results were slightly worse than the company ...

Novo Nordisk A/S (NVO) investors were hit by a train as the leading diabetes and obesity drugs maker's recent CagriSema study didn't impress as its performance came in markedly below its ...

Haemophilia is a rare condition that affects the blood’s ability to clot. Credit: Rembolle via Shutterstock. Novo Nordisk has secured approval from the US Food and Drug Administration (FDA) for Alhemo ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Elsewhere on the hemophilia front, Novo is looking to challenge Roche’s bleeding disorder stalwart Hemlibra, which generated nearly $4.8 billion in sales last year. To take on Roche’s ...

Novo Nordisk has announced its latest trial result ... The figure dropped further to 20.4% when patients failed to adhere to the treatment. The result sparks concerns about the company's ...

The Eight Sleep Pod 4 system starts from £2598 / $2598 for a UK double or Full, £2698 / $2798 for a UK King / US Queen, £2898 / $2998 for a Super King / US King and £3098 / $2998 for an ...

iPhone 4 SE design: What will the next iPhone SE look ... as 64GB isn’t enough for most users anymore, especially since system files take up more than 10GB (and you can add a multi-gigabyte ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...

Novo Nordisk shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90 billion off the valuation of Europe’s largest company by market ...